Jump to content

PYC - PYC THERAPEUTICS LIMITED


ShareCafe

Recommended Posts

Must admit I bailed nearly a year ago - found it one of the most frustrating shares I had got involved in. When I bought there appeared to be good potential but for some reason South was the direction it favoured.

Sincerely hope it pays off in the long run for all holders.

 

Link to comment
Share on other sites

  • Replies 1.5k
  • Created
  • Last Reply

Top Posters In This Topic

Top Posters In This Topic

Posted Images

Phylogica collaborates with Swiss allergy institute

12:22, Thursday, 27 September 2007

 

Sydney - Thursday - September 27: (RWE Aust Business News) -

Phylogica (ASX:PYC) has signed a research collaboration agreement with

the Swiss Institute of Allergy & Asthma Research (SIAF).

The collaboration involves the screening of Phylogica's

proprietary Phylomer libraries for potential vaccine leads for the

treatment of allergies and asthma.

If successful, the program will generate novel vaccine antigens

that can be developed for allergen immunotherapy - the desensitisation of

allergic individuals to common antigens like bee venom and birch pollen.

Moreover, this technology has applicability for the common

house dust mite, pollen and grass allergies.

Phylogica share were up 0.5 to 28c.

ENDS

 

 

Link to comment
Share on other sites

  • 2 weeks later...

In reply to: cobra on Tuesday 25/09/07 11:05pm

QUOTE

Have run out of patience,time to move on ---Good luck to all holders.

 

Guys, two golden rules of biotech:

 

1) It takes longer than you expect

 

2) It costs more than you thought

 

PYC.ASX is in the early stages of developing an "engineering" approach to discovery and development of therapy based on protein silencing.

 

The world is just getting to grips with the RNAi and mRNA developments leading to gene silencing. Investments are growing and the RNAi space is "hot". The latest news of the 2007 Nobel Prize for physiology or medicine confirms this.

 

Phylogica's day in the sun is in the future. My guess is that it will be at least two years before phylomers are recognised by "big pharma" as a "new frontier".

 

Investors should look at PYC.ASX as building an unassailable patent position and "engineering" tools, over this time, to dominate this developing industry.

 

Management and directors are doing very well with current license/royalty/development revenues. However, expect at least one return to shareholders for more capital. We are talking about developing a global leadership position in what could be the next technology wave beyond RNAi.

 

I hope directors do not view Phylogica as some kind of M&A exercise. The company could dominate protein silencing in a manner similar to Alnylam's dominance of gene silencing. Needless to say this could generate fabulous returns for PYC.ASX shareholders.

 

There are many risks ahead - starting with proving the commercial merits of the basic technology.

Link to comment
Share on other sites

 

Phylogica reports 'significant' progreess

10:34, Wednesday, October 10, 2007

 

Sydney - Wednesday - Oct 10: (RWE Australian Business News) -

Phylogica (ASX:PYC) has demonstrated biological activity with its lead

RA compounds developed during its Commercial Ready grant funded program.

These hits, generated against the extracellular CD40 Ligand

target (CD40L), were able to successfully block the binding of a

neutralising CD40L antibody to its target. Moreover, this antagonism was

independently confirmed in assays where Phylomer peptides were shown to

inhibit functional activity of CD40L in living cells.

"This result demonstrates that Phylomer peptides are specific

and bind tightly to the RA disease target," said Phylogica CEO, Dr

Stewart Washer. "We are also excited that we have made such significant

progress on this important project in such a short period of time,

paving the way for testing some of these candidates in animal models of

RA in collaboration with the University of Melbourne next year,"

NDS

 

 

Link to comment
Share on other sites

Biological Validation of Lead Compunds in Rheumatoid Arthritis Programme

 

http://www.pipelinereview.com/joomla/content/view/15107/101/

 

10 Oct 2007

Phylogica demonstrates biological activity for its lead compounds in its Rheumatoid Arthritis programme

 

PERTH, Australia | October 10, 2007 | Phylogica Limited (ASX: PYC) announced today that it has demonstrated biological activity with its lead RA compounds developed during its Commercial Ready grant funded program.

 

These hits, generated against the extracellular CD40 Ligand target (CD40L), were able to successfully block the binding of a neutralising CD40L antibody to its target. Moreover, this antagonism was independently confirmed in assays where PhylomerÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚® peptides were shown to inhibit functional activity of CD40L in living cells.

ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¦ÃƒƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“This result demonstrates that PhylomerÃÆâ€â„¢ÃƒÆ’ƒâ€Â ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒ¢Ã¢â‚¬Å¾Ã‚¢ÃƒÆ’ƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¯ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’‚ ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬ÃƒÂ¢Ãƒ¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¾ÃƒÆ’‚¢ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢ peptides are specific and bind tightly to the RA disease targetÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚ÂÂ, said Phylogica CEO, Dr Stewart Washer.

 

ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¦ÃƒƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“We are also excited that we have made such significant progress on this important project in such a short period of time, paving the way for testing some of these candidates in animal models of RA in collaboration with the University of Melbourne next yearÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚ he added.

 

ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¦ÃƒƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“Phylogica has now developed a comprehensive portfolio of PhylomerÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚® drugs in the areas of burns treatment, cardiac ischemia, stroke/head trauma and RA, valuable markets with strong demands for new drugsÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚ÂÂ. PhylogicaÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s VP Drug Discovery, Dr Paul Watt, commented that ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¦ÃƒƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…âہ“Our hits not only block the activity of CD40L, but they also bind this target with sufficient affinity to compete with well characterised antibodies specific for that target. This has important implications for dosing and cost of goods of any subsequent drug, since these non-optimised PhylomerÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚® hits show encouraging biological efficacy. We have now confirmed the RA hits announced in May are biologically active in cell based assays, clearing the way for progression into animal disease model testing.

 

ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚ These data now mean that Phylogica has demonstrated biological efficacy against both intracellular and extracellular disease targets, making the PhylomerÃÆâ€â„¢ÃƒÆ’ƒâ€Â ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒ¢Ã¢â‚¬Å¾Ã‚¢ÃƒÆ’ƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¯ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’‚ ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬ÃƒÂ¢Ãƒ¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¾ÃƒÆ’‚¢ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢ technology one of the most versatile drug discovery platforms currently available.

 

These results are being presented at BioPartnering Europe in London this week ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã¢â‚¬Å“ this presentation will be available for download from our website www.phylogica.com. The next step is to prepare the lead molecules for animal efficacy testing in 2008 with our collaborator, Prof John Hamilton at the University of Melbourne. This CD40L target is also a validated disease target in many other inflammatory diseases.

 

These include diabetes, IBD, uveitis, thyroiditis, lupus and nephritis. An anti-CD40L mAb (IDEC-131) was tested in clinical trials for Multiple Sclerosis, psoriasis, CrohnÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s disease, and idiopathic thrombocytopenic purpura.

The attached figures show: A) PhylomerÃÆâ€â„¢ÃƒÆ’ƒâ€Â ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒ¢Ã¢â‚¬Å¾Ã‚¢ÃƒÆ’ƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¯ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’‚ ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬ÃƒÂ¢Ãƒ¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¾ÃƒÆ’‚¢ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢ peptide blocking binding of CD40L to neutralising anti-CD40L antibody and B) PhylomerÃÆâ€â„¢ÃƒÆ’ƒâ€Â ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒ¢Ã¢â‚¬Å¾Ã‚¢ÃƒÆ’ƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¯ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’‚ ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬ÃƒÂ¢Ãƒ¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¾ÃƒÆ’‚¢ÃƒÆ’Æâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢ peptide blocking of biological activity of CD40L in primary white blood cells.

 

B) Dose response curve of PhylomerÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚® peptide, PYC18 inhibiting expression of CD40L-induced CD86 on primary B cells

 

A) PhylomerÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚® peptide, PYC18 blocks binding of CD40L to neutralising anti CD40L antibody

 

Phylogica Ltd (ASX:PYC) (www.phylogica.com)

 

Phylogica is a biopharmaceutical company with an advanced technology (known as PhylomerÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚® peptides) that is being applied to develop a new class of drugs for emergency treatment of burns, traumatic brain injury and other inflammatory diseases including rheumatoid arthritis.

Phylogica was founded by the Telethon Institute for Child Health Research in Perth (www.ichr.uwa.edu.au) and the Fox Chase Cancer Center in Philadelphia, United States (www.fccc.edu).

 

About PhylomerÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚® peptides

 

PhylomerÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚® peptides are stable fragments of naturally-occurring proteins with the ability to bind tightly to target proteins and inactivate them as a result. PhylomerÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚® peptides can be selected for activity against specific disease target proteins. The properties of PhylomerÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚® peptides make them attractive as cost effective alternatives to antibodies (a proven multi-billion drug class) and also work against disease targets that antibodies cannot reach (inside the cell). Phylogica's proprietary PhylomerÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚® libraries are collections of millions of PhylomerÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚® peptides that represent a source of drug leads which can be used for multiple diseases.

 

SOURCE: PHYLOGICA LIMITED

 

Link to comment
Share on other sites

  • 2 weeks later...

 

PHYLOGICA to take burns drug to human trials

12:34, Tuesday, 23 October 2007

 

Sydney - Tuesday - October 23: (RWE Aust Business News) -

Phylogica (ASX:PYC) will progress its lead candidate for burns, PYC35B,

to human trials in 2008.

The company received excellent results from the latest

pre-clinical study conducted independently by Fiona Wood's McComb

Foundation.

The dose response using the Phylomer peptide D-PYC35B in a mouse

wound repair model found that, at a low concentration, there was a

significant improvement in both the rate of healing as well as scar

reduction.

ENDS

 

 

Link to comment
Share on other sites

  • 1 month later...

It seems like all these biotech players want to sell the hope and optimism they see in their science gilded with promises while the reality is all they can actually provide is bile. The sahre price has depreciated back to its IPO price.

 

Even though they talk of big pharma interest, the sector in play with reference to other big deals (all US based), the fact of the matter is they are long on optimism and short on the detail.

 

Even the CEO talks big promising a deal with big pharma tests pending, but no confidence elucidated as to when, who or any sort of commercial value or structure.

 

This is nothing specific to this company. We have seen it at VLA, XBL, PRR, SPL, VHL, and BLT. They are just the ones I take an interest in. I dare say it is endemic in the industry.

 

I am shifting from thinking these people are full of s**t to being quite confident in openly declaring them as such despite their science capabilities they don't quite seem to grasp the fact they operate in a commercial environment.

 

Disc: I hold no PYC. Pity the poor b*****d's who do.

Link to comment
Share on other sites

  • 2 weeks later...

In reply to: plastic on Thursday 06/12/07 04:23pm

plastic -they were my 1st thoughts when reading the ASX ann.

 

Keep talking the deal & it only has to be reported when the deal is done(signed)

 

Good buyer support in the low 20's & hardly any on offer which would be a good time for a buy up.

 

Patience needed with PYC.

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

×
×
  • Create New...